[{"address1": "100 Campus Drive", "city": "Florham Park", "state": "NJ", "zip": "07932", "country": "United States", "phone": "608 441 8120", "website": "https://www.cellectar.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Mr. James V. Caruso", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1142418, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chad J. Kolean CPA", "age": 59, "title": "VP, CFO & Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 711230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jarrod  Longcor", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 854242, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darrell Shane Lea", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrei  Shustov M.D.", "age": 51, "title": "Senior Vice President of Medical", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.93, "open": 1.94, "dayLow": 1.865, "dayHigh": 1.94, "regularMarketPreviousClose": 1.93, "regularMarketOpen": 1.94, "regularMarketDayLow": 1.865, "regularMarketDayHigh": 1.94, "beta": 0.987, "forwardPE": -0.6749117, "volume": 197245, "regularMarketVolume": 197245, "averageVolume": 637488, "averageVolume10days": 652180, "averageDailyVolume10Day": 652180, "bid": 1.89, "ask": 1.94, "bidSize": 100, "askSize": 100, "marketCap": 68471400, "fiftyTwoWeekLow": 1.57, "fiftyTwoWeekHigh": 4.45, "fiftyDayAverage": 2.6044, "twoHundredDayAverage": 3.01165, "currency": "USD", "enterpriseValue": 46783896, "floatShares": 27086013, "sharesOutstanding": 35848900, "sharesShort": 2217737, "sharesShortPriorMonth": 2367004, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0619, "heldPercentInsiders": 0.03202, "heldPercentInstitutions": 0.32048, "shortRatio": 4.26, "shortPercentOfFloat": 0.070199996, "bookValue": 0.274, "priceToBook": 6.9708033, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -50983864, "trailingEps": -3.09, "forwardEps": -2.83, "lastSplitFactor": "1:10", "lastSplitDate": 1531785600, "enterpriseToEbitda": -1.113, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CLRB", "underlyingSymbol": "CLRB", "shortName": "Cellectar Biosciences, Inc.", "longName": "Cellectar Biosciences, Inc.", "firstTradeDateEpochUtc": 1131633000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d92a6d57-8c29-3e38-89dc-584b57cac7f0", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.91, "targetHighPrice": 25.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.6, "targetMedianPrice": 12.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 40031180, "totalCashPerShare": 1.117, "ebitda": -42018520, "totalDebt": 548343, "quickRatio": 2.461, "currentRatio": 2.543, "debtToEquity": 2.096, "returnOnAssets": -0.91470003, "returnOnEquity": -3.04376, "freeCashflow": -15485470, "operatingCashflow": -38554944, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-12"}]